Bio-Path presents positive interim Phase 2 prexigebersen AML data at ASCO and EHA

BIO-PATH HOLDINGS, INC.

ASCO oral presentation on June 1, 2024 (8:00 AM CT, McCormick Place, abstract #6511).
EHA poster presentation on June 14, 2024 (6:00 PM CEST, Madrid, abstract #P536).
Interim Phase 2 data for prexigebersen (BP1001) plus decitabine/venetoclax in AML show it's well-tolerated with compelling efficacy.
Data from newly diagnosed and refractory/relapsed cohorts both exceeded outcomes with frontline therapy.
No specific numerical results were disclosed in the press releases.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.